Chinese mRNA company Stemirna Therapeutics has halted an early-stage trial of a cancer vaccine, according to a Reuters report.
Researchers working on the trial have been quoted in the report as saying that the trial of the Shanghai-based company’s vaccine SW1115C3, in malignant solid tumors, has been on hold for several months.
This latest setback follows reports in December that Stemirna had been unable to make wage payments to staff and was struggling to raise fresh financing. Chinese media have also reported on the company’s debts and legal woes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze